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Abstract
Background: Community pharmacies are major contributors to health care systems across the world. Several studies
have been conducted to evaluate community pharmacies services in health care. The purpose of this study was to
estimate the social and economic benefits of current and potential future community pharmacies services provided by
pharmacists in health care in Portugal.
Methods: The social and economic value of community pharmacies services was estimated through a decision-model.
Model inputs included effectiveness data, quality of life (QoL) and health resource consumption, obtained though literature
review and adapted to Portuguese reality by an expert panel. The estimated economic value was the result
of non-remunerated pharmaceutical services plus health resource consumption potentially avoided. Social and
economic value of community pharmacies services derives from the comparison of two scenarios: “with service” versus
“without service”.
Results: It is estimated that current community pharmacies services in Portugal provide a gain in QoL of 8.3% and an
economic value of 879.6 million euros (M€), including 342.1 M€ in non-remunerated pharmaceutical services and 448.
1 M€ in avoided expense with health resource consumption. Potential future community pharmacies services may
provide an additional increase of 6.9% in QoL and be associated with an economic value of 144.8 M€: 120.3 M€ in non-
remunerated services and 24.5 M€ in potential savings with health resource consumption.
Conclusions: Community pharmacies services provide considerable benefit in QoL and economic value. An increase
range of services including a greater integration in primary and secondary care, among other transversal services, may
add further social and economic value to the society.
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Background
Health care systems have suffered several challenges due
to the financial crisis that affected Europe in recent years
[1]. Portugal, amongst other countries, has implemented
several measures in order to curb health care costs [2].
As a consequence, from 2011 to 2014, total health ex-
penditure decreased more than 6%, to a level of 15,681.9
million euros (M€) in 2014, which represented, approxi-
mately, 9.1% of the Gross Domestic Product (GDP) [3].
The substantial reduction of Public Health expenditure
may have a direct impact on health care services,
originating consumption restraints and ultimately limit-
ing access to health care [4–7].
Community pharmacists are major contributors to
health care system across the world. The role of the
pharmacist in the community has evolved throughout
the years, shifting from medicines to a patient-centred
approach with increased provision of clinical pharmacy
services [8–10]. Pharmacists are particularly qualified to
provide pharmacotherapeutic counselling, monitor ther-
apy outcomes, contribute to decrease the risk for unin-
tentional adverse events and prevent drug interactions
[11–15]. In addition, community pharmacists are
uniquely positioned within the health care system,* Correspondence: diana.ferreira@exigoconsultores.com
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having established a widespread network of services that
provide direct outpatient care.
Hence, it is vital to promote health interventions that
contribute, not only to a widespread access to health
care, but also to more efficient resource allocation.
Several systematic literature reviews and meta-analysis
that evaluate the impact of community pharmacies services
in health care have been conducted, revealing positive im-
pacts on patient’s outcomes, as well as economic benefits
[10, 16–18]. Specifically, services provided in cardiovascular
diseases showed a significant impact on systolic and dia-
stolic blood pressure, with reductions of 6.1 mmHg and
2.5 mmHg, respectively [19]. Moreover, there is evidence
suggesting that reducing diastolic blood pressure
(−2 mmHg) results in a 6% and 15% risk reduction of cor-
onary heart disease and stroke and transient ischemic at-
tacks, respectively [20]. Pharmaceutical services in diabetes,
asthma, smoking cessation or syringe-exchange programs
have also demonstrated health gains in the enrolled popula-
tion [11, 21–23]. Notwithstanding the positive clinical ben-
efits, these services also represent cost-effective measures,
leading to lower direct medical costs [21, 24–26].
In Portugal, all community pharmacies are privately
owned and, similarly to other countries, their core activity
is to dispense prescription and non-prescription medicines.
Even tough community pharmacies hold the exclusivity of
the first, since 2005, dispensing of the latter was authorised
outside of community pharmacies. Since 2007, the range
of pharmaceutical services provided has been widened
with the introduction, for example, of immunization ser-
vices (i.e., vaccines not included in the Nacional Vacci-
nation Plan), disease management campaigns, health
campaigns and home care support. It should be noted that
community pharmacies in Portugal are not reimbursed by
the National Healthcare System for the provision of any of
these services, but patients pay out-of-pocket for some of
them [27, 28].
A study conducted by Félix et al. [29] evaluated the im-
pact of community pharmacies’ participation in the na-
tional syringe-exchange program. This study estimated
that 7000 new human immunodeficiency virus (HIV) in-
fections were avoided during the first 8 years of the pro-
gram, resulting in overall economic savings of 400 M€ in
health care costs related to HIV [29]. Nonetheless, to date,
no study has been conducted in Portugal to globally esti-
mate the social and economic value of the full range of ser-
vices delivered by community pharmacists. Therefore this
study aimed to estimate the social and economic benefits
of current and potential future community pharmacies ser-
vices provided by pharmacists in health care, in Portugal.
Methods
The conceptual model developed evaluated the impact of
community pharmacies services through the comparison
of two scenarios: “with service” and “without service”. The
model was designed to consider micro outcomes to evalu-
ate the effectiveness of each service and macro outcomes,
such as quality-adjusted life years (QALYs) and health re-
source consumption, to allow the assessment of the aggre-
gated social and economic value of all the services.
The definition of the list of services included required
the identification of services already provided by the
Portuguese community pharmacies (current services) and
potential services that could be implemented (potential
future services).
In order to parameterize the model, a literature review
was conducted to identify the specific outcomes of every
service evaluated, including disease specific, QoL and re-
source consumption.
The model was adapted and validated to the national
reality by an expert panel.
Fig. 1 depicts briefly the steps taken in this project.
Conceptual model
A decision model was developed to estimate the social
and economic value of community pharmacies services
(Fig. 2). The comparison of both scenarios involved sev-
eral outcomes divided in three classes: therapeutic area-
specific, social and economic. Therapeutic area-specific
outcomes consisted, for example on blood pressure in
hypertension or glycated haemoglobin in diabetes.
QoL and health care resource utilisation were regarded
as social outcomes; and economic outcomes included
non-remunerated community pharmacies services costs
and health care resource utilisation costs avoided (Fig. 2).
Finally, the specific, social and economic evaluations
were the result of the difference between the scenario
with and without services delivered at community phar-
macies. Services that are not entirely focused on one
particular clinical outcome but instead have a broader
range were evaluated separately and only included the
economic value.
The model adopted a 1-year time horizon (2014) and
the societal perspective.
Pharmaceutical services included in the model
Current services are already being provided by
Portuguese community pharmacies, for example, disease
management programs, smoking cessation, specific
counselling, among others (Additional file 1: Table S1).
These were retrieved from data from Centre for Health
Evaluation & Research (CEFAR) and from public docu-
ments that specify the services that can be performed in
pharmacies in Portugal [27, 30, 31]. Potential future ser-
vices comprised services that could be provided in
Portuguese community pharmacies, including services
that were once provided by Portuguese community
pharmacists but have been discontinued, services
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performed in other countries and not yet implemented in
Portugal, services tested as part of pilot studies that have
also been discontinued and interesting services that
should be developed by national community pharmacies,
some already included in a recent legal order issued by the
Portuguese government (Additional file 2: Table S2) [32].
Finally, the services which included a broader range of
action included: medicines wastage, syringe exchange
program, medicines disposal program (Valormed), re-
search projects and pharmaceutical students’ curricular
internships.
Literature search and data extraction
An extensive comprehensive search in MEDLINE
(PubMed) was conducted in order to identify the disease
specific and economic outcomes of pharmaceutical
Fig. 2 Conceptual Model
Fig. 1 Summary study methodology
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services. The search included articles published before
July 2015 studying pharmaceutical services in the com-
munity pharmacy context. The search strategy included
terms for the pharmacist or community pharmacy,
pharmaceutical services and social and economic end-
points (Additional file 3: Table S3). Language restrictions
were adopted for English and Portuguese articles. A
search in Google and GoogleSchoolar was also con-
ducted to find any additional or grey literature. In
addition, studies reporting on national community phar-
macies services presented at congresses or available as
reports were requested to CEFAR.
Inclusion criteria included services or observational
studies conducted either in community pharmacies with
results (clinical, social or economic) before and after the
service implementation or in participants’ groups with
and without service. Studies included in the quantitative
synthesis had to report endpoints of interest (clinical,
social and/or economic). Unoriginal work (reviews,
meta-analysis, editorials and letters to the editor),
pharmaceutical services performed in hospitals or in the
health maintenance organization setting, or projects
conducted by pharmacy students were excluded.
Whenever the abstract had insufficient detail to assess
for inclusion criteria, the record was included for full-
text revision. After reviewing titles and abstracts, a hard
copy of each record that met inclusion criteria was ob-
tained for full-text review.
Data from studies that met inclusion criteria were ex-
tracted from each record: author, year of publication,
condition targeted, number of patients enrolled and out-
comes reported (clinical, social or economic) before and
after the service implementation or in the control and
intervention groups.
Expert panel
After data extraction, a synthesis of the reviewed data
was presented to a national expert panel of seven phar-
macists, specialists in pharmaceutical care, and two phy-
sicians. The pharmacists were selected based on their
experience in pharmaceutical services in community
pharmacies and are all considered experts in this field;
additionally, the panel presented geographic heterogen-
eity. Physicians selected present deep knowledge and
vast experience in the relation between community
pharmacies and primary care, and as so were able to
quantify the impact of pharmaceutical services in pa-
tients’ QoL and at an economic level. All the experts
gave their oral consent for participating in this study.
Experts were asked to validate and adjust collected
data to the Portuguese reality according to their experi-
ence and expectations, and whenever data was unavail-
able, experts were asked to suggest an estimated value
based on their experience. Data was collected individu-
ally from each expert in order to reflect the possible het-
erogeneity in their practice; no consensus was aimed to
be achieved.
A meeting was held with the pharmacists’ expert panel
in order to discuss the pharmaceutical services included
in the model, covered population, time spent by a
pharmacist in a specific service, number of services per-
formed and specific endpoints related to the therapeutic
area, whenever this information was lacking in the litera-
ture or not available from CEFAR data. For this meeting,
Fig. 3 PRISMA flow-chart of literature review
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data collection was obtained with an electronic system,
which required the experts to answer the questions in a
device connected to the software. After all experts had
provided their responses, aggregated mean values and
standard deviations or frequency of responses, were
automatically presented in the computer screen. Invited
physicians were interviewed individually regarding data
about health resource consumptions and QoL. Both
meetings with the physicians were conducted using a
structured questionnaire where their answers were
noted. No interview guide was developed, but all the
meetings were conducted by the same person in order
to guarantee homogeneity in data collection.
Following the expert panel meeting, mean estimated
values were incorporated in the model. Services consid-
ered irrelevant in the Portuguese context by the pharma-
cist experts were excluded from the model.
Resources utilisation and costs
The annual number of community pharmacies services
was directly obtained from the study conducted by Pita
Barros et al. [33], which was further completed with data
directly requested to the authors. The amount of annual
services was then divided by the mean number of annual
services per patient, thus obtaining the covered popula-
tion. Whenever the amount of a specific service was not
available in the study by Pita Barros et al. [33], data was
provided by CEFAR. CEFAR possesses data from a rep-
resentative sample of community pharmacies from
which the annual number of pharmaceutical services
and their respective cost for the patient can be extracted;
however, not all community pharmacies register services
provided, particularly when services are free of charge. If
the amount of a specific service was not available in the
study by Pita Barros et al. neither in CEFAR data, the es-
timated mean number of services provided per year was
elicited by the expert panel of pharmacists.
The economic value provided by non-remunerated
pharmaceutical services derived from the pharmacy cost
per minute (0.53€) [34] multiplied by the time spent on
each service, obtained from the study conducted by Pita
Barros et al. [33], and by the estimated number of ser-
vices performed. Whenever adequate, the resulting cost
was then subtracted by the patients’ charged price, ob-
tained from CEFAR data [34, 35].
Concerning the economic impact of pharmaceutical
services, the cost of a physician visit was estimated con-
sidering the costs and the number of physician visits
performed. The cost of each physician visit used (67.02
€) is a weighted average [36] of the cost of primary care
general practitioner visit in Portugal (68.60€) [37] and
the cost of specialist visit (63.19 €) in secondary care
(the cost of a secondary care visit was retrieved from a
Ministry of Health source which stipulates the agreed
cost to pay the hospitals for that visit, this value may be
lower than the actual value of the visit) [38].
A similar cost estimating process was used for the
emergency-room visits. Hospital funding regarding
emergency-rooms is allocated based on three types of emer-
gency services and respective funding levels [38]. The cost
of each level was then multiplied by the number of
emergency-rooms visits performed on the hospitals of each
level [36]. As a result, the average weighted cost incorpo-
rated in the model for an emergency-room visit was 71.86 €.
The average cost of hospitalisation was directly collected
from the Contract Program of Central Administration of
the Health System (2,120.28 €), except for hospitalisation
related to diabetes, asthma, hypertension, blood coagula-
tion variations, chronic obstructive pulmonary disease
(COPD) and dyslipidaemia [38]. For these situations, a
specific cost was estimated for each therapeutic area, link-
ing the International Classification of Diseases (ICD-9)
with the respective most frequent codes of the diagnosis-
related groups (DRG). The proportion of selected DRG
and the associated price were validated by the physician
experts.
The social and economic impact in specific chronic
conditions was included in the value provided by overall
current community pharmacies services.
Other current services (syringe-exchange program,
medicines disposal program and research projects) were
evaluated according to the time spent by the pharmacist
multiplied by the pharmacy cost per minute [34]. The
additional value for money of the syringe-exchange pro-
gram was estimated in a previous study, conducted in
Portugal in 2002 [29] and updated using the Consumer
Price Index variation for 2014 (the last year available)
and then multiplied by the number of syringes ex-
changed when community pharmacies were not involved
in the syringe exchange national program (year 2013).
The economic value associated with the medicines
wasted management took into account the role of phar-
macists in the promotion of patient adherence and con-
sequently the mean number of packages consumed due
to the service. The latter was then multiplied by the cost
per package attributable to non-adherence, previously
described in the literature (2.85 €) [39].
The non-remunerated value related to the services of
community pharmacies in pharmaceutical students’ cur-
ricular internships was assessed by allocating the propor-
tion of faculty fees corresponding to the pharmaceutical
students’ curricular internship in the pharmacy, which is
currently granted to the faculties.
Results
Literature review
The literature review identified 42,919 records in MED-
LINE (PubMed) and 43 additional records (posters and
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reports) were provided by CEFAR (Fig. 3). The initial
screening process, through title and abstracts reading,
excluded mainly opinion articles or articles reporting
secondary data (derived from literature reviews or meta-
analysis). The most common reasons for exclusion after
full-text reading were records of services provided by
hospital pharmacies, health maintenance organizations,
services conducted by pharmacy students or not evaluat-
ing services previously selected to be included in the
model.
Expert panel
The expert panel decided consensually that some pro-
posed services should be removed from the model. In
current services, inspection of first aids kits was re-
moved, due to the low availability of this service in Por-
tuguese community pharmacies. Also, in potential future
services, alcohol cessation and collection of biological
products were removed since they were considered a
multidisciplinary service not performed exclusively by
pharmacists.
Current services
The social and economic value of community pharma-
cies services is depicted in Table 1. The added value of
community pharmacies services was the result of the dif-
ference between a scenario with and a scenario without
the evaluated services. Table 1 also identifies the esti-
mated population covered in total (which represents
40.3% of the Portuguese population), the total number
of services and total pharmaceutical time spent to pro-
vide such services.
It is estimated that current community pharmacies
services represent a gain of 8.3% in QoL, providing
260,245 additional QALYs to the covered population in
the year of 2014 (Table 1). The aggregated economic
value provided by current services represents an added
value to the society of 879.6 M€ (Table 1). This value is
further divided in three main areas: 50.9% related to
health care resource utilisation (448.1 M€), 38.9% from
non-remunerated pharmaceutical services related with
specific therapeutic areas (342.1 M€) and 10.2% from
other non-remunerated pharmaceutical services with
Table 1 Social and economic value of the current community pharmacies services
Current services
With service Without service Difference
Population Covered (n) 4,180,190 4,180,190 0
Estimated number of pharmaceutical services (n) 120,675,438 0 120,675,438
Time spent in services (hours) 11,087,135 0 11,087,135
Social Value
Quality of Life
Quality of Life (growth rate, %) 0.813 0.751 0.062 (+8.3%)
Quality adjusted life years 3,399,191 3,138,946 260,245
Health Resource Utilisation (n) 20,818,175 26,853,745 −6,035,571
Physician visits (n) 17,881,598 23,872,706 −5,991,108
Emergency-room visits (n) 2,871,217 2,893,271 −22,054
Hospitalisations (n) 65,359 87,768 −22,409
Economic Value
Total cost (€) 1, 192.2 M€ 2, 071.9 M€ −879.6 M€
Community pharmacy (€)
Community pharmacist’ service (monetary compensated and non-monetary compensated) −352.1 M€ 0.0 € −352.1 M€
Patients 10.0 M€ 0.0 € 10.0 M€
Cost of Health Resource Utilisation (€)
Physician visits 1, 198.4 M€ 1, 599.9 M€ −401.5 M€
Emergency-room visits 206.3 M€ 207.9 M€ −1.6 M€
Hospitalisations 134.4 M€ 179.4 M€ −45.0 M€
Other costs (€)
Medicines waste management 14.9 M€ 85.0 M€ −70.1 M€
Syringe exchange program −6.3 M€ −0.3 M€ −6.0 M€
Others −13.4 M€ 0 −13.4 M€
M€, Million euros
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value for the society (89.5 M€). These other services
comprise community pharmacists’ contributions to med-
icines wastage management, syringe-exchange program,
voluntary participation in the Valormed program (medi-
cines disposal program), research projects and contribu-
tions to pharmaceutical students’ curricular internships.
Together, the services on medicines wastage and
syringe-exchange programs are estimated to generate a
value of 76.1 M€ to society.
Previous results can be further detailed in three major
health areas: chronic conditions/therapies, mother and
child health and transversal services, which may have
held societal values of 187.6 M€, 13.3 M€ and 589.3 M€,
respectively. Services provided in chronic conditions/
therapies are estimated to have a positive impact of 8.0%
increment in QoL, having allowed 120,604 additional
QALYs in 2014. Moreover, these sets of services are esti-
mated to avoid 1,480,442 physician visits, 13,101
emergency-room visits and 12,962 hospitalisations.
Mother and child health services are estimated to cover
annually 654,285 mothers or children and to provide a
0.2% increase in QoL, with an added economic value of
13.3 M€. Evidence suggests that mother and child ser-
vices do not impact health resource utilisation and
therefore the economic value provided derives exclu-
sively from non-remunerated community pharmacies
services. Transversal services include services in several
areas, such as non-prescription medicines counselling,
multidose drug dispensing or domiciliary support. These
services are estimated to increase QoL in 12.7% and hold
an economic value to society of 589.3 M€ (266.3 M€ in
non-remunerated community pharmacies services and
323.0 M€ in avoided costs with health resource utilisa-
tion). In this specific setting (transversal services), a total
of 4,510,665 physician visits, 8953 emergency-room
visits and 9446 hospitalisations were estimated to have
been avoided due to community pharmacies services.
Services in specific chronic conditions
Within chronic conditions, the two areas where com-
munity pharmacies services were most valued were
hypertension and diabetes. Services provided in hyper-
tension are estimated to cover 828,216 patients and to
be associated with an average reduction of 14.5 mmHg
(standard error: 4.0 mmHg) in mean systolic blood
pressure. A QoL increment of 5.7% is estimated in the
covered population, representing a benefit of 33,129
additional QALYs. Other social benefits comprise
1,549,094 avoided physician visits, 7557 avoided
emergency-rooms visits and 7557 avoided hospitalisa-
tions. Estimated added economic value totalizes
147.6 M€: 119.3 M€ representing savings in health re-
sources’ utilisation and 28.3 M€ provided by non-
remunerated community pharmacies services.
Regarding services in diabetes, a total of 286,186 covered
patients were estimated with a decrease in glycated haemo-
globin of 0.7 percentage points. The estimated social value
achieved a 4.7% gain in QoL and 10,707 additional QALYs.
The utilisation of pharmacy services was estimated to avoid
279,807 medical acts: 274,577 physician visits, 2615
emergency-room visits and 2615 hospitalisations.
Potential future services
Pharmaceutical services potentially considered in the
near future but not yet provided in community pharma-
cies, such as, repeat dispensing, patient call-back systems
or medication reconciliation (from inpatient to out-
patient setting) were also evaluated.
Overall future community pharmacies services may in-
crease QoL by 6.9% in 1,724,274 additional patients to
be potentially covered (16.6% of the Portuguese popula-
tion). This increment could possibly be translated in
75,640 additional QALYs. Moreover, it could eventually
have an impact on health resource consumption, avoid-
ing 363,608 physician visits, 39 emergency-room visits
and 39 hospitalisations. The added economic value of
the broader range of potential future community phar-
macies services may achieve 144.8 M€ (Table 2).
The evaluation of the potential future services can be
further divided in three categories: integration with pri-
mary care, integration with secondary care and transver-
sal services.
Integration with primary care could lead to an increase
in QoL by 4.0% and a gain of 23,116 additional QALYs.
The estimated economic value provided to society could
sum up to 110.2 M€, which is the result of 102.5 M€ in
non-remunerated pharmaceutical services, 7.7 M€, 2.8
thousand € and 81.721 thousand € in avoided physician
visits, emergency-room visits and hospitalisations,
respectively.
Integration with secondary care contemplated the pos-
sibility of community pharmacies to dispense medicines
currently dispensed exclusively at hospital pharmacies or
to adjust dosing regimens in anticoagulation therapy,
among others. These sets of services are estimated to in-
crease by 10.2% the QoL of the potentially covered
population (835,703 patients) and to add 52,309 QALYs.
The economic value provided to society could be the re-
sult of non-remunerated community pharmacies services
(11.0 M€) and prevented physician visits (16.7 M€),
summing 27.7 M€. Finally, transversal services might
benefit the society in 6.8 M€ and lead to a 1.1% increase
in 26,185 patients’ QoL.
Discussion
From 2011 until 2014, Portugal was subject to an inter-
national financial assistance program which led to the
implementation of several austerity measures impacting
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the socio-economic conjecture of the country [40]. The
Portuguese National Health Service has recently cele-
brated 35 years of existence, health policy challenges to
sustain the basic principles of its foundation – universal
and general coverage, equity in access and tending to-
wards free services – have been in the horizon [41]. In
order to preserve such values, it is urgent to efficiently
allocate resources and to promote structural reforms in
health care services.
Community pharmacists already play a crucial role in
Public Health and their widespread network of services
is an important asset in access to healthcare. Therefore,
the purpose of this study was to estimate the social and
economic value of current and potential future commu-
nity pharmacies services in health care, in Portugal.
From the social perspective, the current estimated an-
nual value of pharmaceutical services in the community
is an overall increment in QoL of 8.3%, representing
260,245 additional QALYs. Moreover, potential future
services could be accountable for an additional increase
of 6.9% in QoL and 75,650 QALYs.
The economic value of community pharmacies services
was demonstrated by the generated 879.6 M€ savings, at-
tributable mainly to the health resource utilisation averted
and the non-remunerated services of pharmacists. Putting
these results into context, the generated 879.6 M€ savings
represented 5.6% of the Portuguese Public Health expend-
iture and 0.5% of the GDP, in 2014 [3]. Savings could
amount to more 144.8 M€ if one considers the potential
future integration of community pharmacies in primary
and secondary care services and other transversal services.
This is the first study that has ever suggested social
and economic value for nationwide services of commu-
nity pharmacies. Previously published systematic reviews
also demonstrated clinical, social and economic benefits
of specific community pharmacies services worldwide
[16, 18, 42–44]. Overall assessment produced a positive
impact on clinical, social and economic endpoints,
which is in line with the present study results. Most
international studies, focused on particular diseases or
conditions, showed favourable results in clinical end-
points such as glycated haemoglobin, lipid parameters or
blood pressure [11–13, 21, 45], which was concordant
with other Portuguese published studies [46–51]. These
studies reported mainly outcomes in patients with dia-
betes, hypertension, dyslipidaemia, asthma or COPD.
For example, a meta-analysis of pharmaceutical services
showed a decrease in glycated haemoglobin of 1.8%,
whereas this study conducted in Portugal suggest a re-
duction of 0.7%; and for systolic and diastolic blood
Table 2 Social and economic value of the future community pharmacies services
Potential future services
With service Without service Difference
Population Covered (n) 1,724,274 1,724,274 0
Estimated number of pharmaceutical services (n) 46,870,802 0 46,870,802
Time spent in services (hours) 3,807,870 0 3,807,870
Social Value
Quality of Life
Quality of Life (growth rate, %) 0.684 0.640 0.044 (+6.9%)
Quality adjusted life years 1,178,882 1,103,242 75,640
Health Resource Utilisation (n) 8,079,565 8,443,250 −363,685
Physician visits (n) 6,848,352 7,211,960 −363,608
Emergency-room visits (n) 1,215,835 1,215,873 −38
Hospitalisations (n) 15,379 15,417 −38
Economic Value
Total cost (€) 458.1 M€ 602.9 M€ −144.8 M€
Community pharmacy (€)
Community pharmacist’ service (monetary compensated and non-monetary compensated) −120.3 M€ 0 € −120.3 M€
Patients 0 € 0 € 0 €
Cost of Health Resource Utilisation (€)
Physician visits 459.0 M€ 483.3 M€ −24.4 M€
Emergency-room visits 87.4 M€ 87.4 M€ 0.0 M€
Hospitalisations 32.1 M€ 32.2 M€ −0.1 M€
M€, Million euros
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pressure, this meta-analysis presented a mean decrease
of 7.8 mmHg and 2.9 mmHg, respectively, which were
higher than the reductions considered in this study of
3.4 mmHg and 1.5 mmHg, respectively [17, 48]. Services
in weight management, smoking cessations or adherence
by both national and international literature were re-
ported in other studies and also evaluated in this eco-
nomic model [49, 52, 53]. A recent systematic review of
cost-effectiveness of professional pharmacy services con-
cluded that community pharmacies services may im-
prove patients’ health with a beneficial economic impact
to health care systems, which was in line with the
current study [44].
Throughout the literature review it was noteworthy
the surplus of studies conducted in the United Stated of
America (USA), in comparison with other countries. In
fact, USA was pioneer in implementing a set of mea-
sures to acknowledge community pharmacies and their
role in providing pharmaceutical care, such as the possi-
bility for flu vaccine administration and other health
care programmes [18, 54]. This set of measures pro-
motes the integration of pharmacists in the health care
team and advocates for the provision of pharmaceutical
care [17]. Another study conducted in Ireland showed
that favourable policy incentives may lead to a better
quality of pharmaceutical services [55], reinforcing the
contribution of each countries’ pharmaceutical policies
in promoting services with great value to the health care
system.
Being a pioneer research in this field, this study bears
limitations and caveats that must be addressed. First of all,
community pharmacies services have existed for several
decades. Hence, a scenario which simulates the absence of
pharmaceutical services is almost impossible to achieve,
and so no natural comparator scenario was possible. On
the other hand, this study also anticipated some of the
consequences that hypothetical future services might have
in health care.
Despite the assumptions associated with future services,
it is important to point out that some of the included ser-
vices had already been provided or piloted in Portugal and
others are already delivered in other countries. In the lat-
ter case, simulations were supported by studies previously
conducted in other countries and validated by the expert
panel. As such, results presented must be interpreted hav-
ing these limitations into consideration.
Throughout the conducted literature review, there was
a limited availability of studies reporting QoL and health
resource utilisation. Moreover, it was observed that the
likelihood of reporting QoL and economic data was as-
sociated with the robustness of the service that was con-
sequently associated with positive outcomes, which in
itself may be a source of bias [11, 12, 21]. Despite this
limitation, data retrieved from internationally performed
services were always subjected to expert validation, in
order to adjust data to the Portuguese context.
Published evidence of pharmaceutical care is mostly de-
rived from USA [17, 18, 56], whose health care system
presents major differences in comparison with Europe.
Nevertheless, accounted differences regarding health re-
source consumption were adjusted to the Portuguese con-
text by national expert physicians. Also, costs associated
with health resource utilisation were exclusively retrieved
from national sources.
Despite the limitations, the expert panel was granted
the possibility to exclude services not considered rele-
vant in the national setting. Consequently, the developed
model included exclusively pertinent services provided
by Portuguese community pharmacists, validated by
Portuguese experts, which could reduce the potential
impact that outcomes of services conducted internation-
ally might have when transposed to the national context.
Furthermore, this study evaluated, simultaneously, a
substantial amount of services from three major per-
spectives: clinical, social and economic. The definition of
clinical outcomes allowed a micro evaluation of each
service separately. Further aggregation and comparison
of services was possible due to the inclusion of macro
outcomes, such as QoL (social) and costs associated with
health resource utilisation (economic).
Another accounted advantage was the contribution of
CEFAR that provided real-world data on services con-
ducted and prices charged to the patients, within a rep-
resentative sample of community pharmacies (more
than 75% of Portuguese community pharmacies). Al-
though much of the research conducted by CEFAR was
not published, it represents the national reality and may
reduce the impact of publication bias.
Moreover, the cost of pharmaceutical activities and
time spent with services used to estimate non-
remunerated pharmaceutical services were retrieved
from previously conducted studies in Portugal with a
representative sample of community pharmacies, redu-
cing the potential impact that services led elsewhere
could have had on the developed model [33–35].
Further studies with sound clinical, social and eco-
nomic outcomes are needed in order to build a growing
body of evidence of cost-effectiveness of community
pharmacies services. Accurate real-world studies, with
control groups, evaluating clinical, social and/or eco-
nomic outcomes of pharmaceutical services in several
therapeutic areas, for instance, diabetes, hypertension,
asthma or dyslipidaemia, should be promoted in order
to update the current model with services conducted in
the Portuguese real-life context and real-world data.
In 2007, the Portuguese legislation recognised commu-
nity pharmacies as adequate sites to provide pharma-
ceutical services, allowing several services to be provided
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by community pharmacists [57, 58]. In 2014, an agreement
between National Association of Pharmacies and the Min-
istry of Health established several services such as the re-
start of the syringe-exchange program in community
pharmacies, and the promotion of medication adherence
in diabetes patients to promote Public Health [59]. More
recently, the government has established the intention to
enhance community pharmacies services in order to pro-
mote the rational utilisation of medicines, close relation-
ship with the National Health System and delegate services
currently available at hospital level, namely the supply of
medicines for oncology and transmissible diseases, cur-
rently exclusively available at hospital pharmacies [32].
Conclusions
In conclusion, this study highlights the importance of
community pharmacies services in health care, revealed
by the high social impact on patients’ QoL and the sub-
stantial economic value to society. Similarly to other
countries, policy and economic incentives to pharma-
ceutical services conducted in community pharmacies
are justified and may further lead to an increased social
and economic benefit on a broader range of patients.
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